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A B S T R A C T
Background: Patients with coronary heart disease (CHD) without classical cardiovascular risk factors
(CRFs) are uncommon, and their proﬁle has not been thoroughly studied. In CHD patients, we have
assessed the differences in several biomarkers between those with and without CRF.
Methods: We studied 704 patientswith CHD,analyzing plasma levelsof biomarkers related to inﬂammation,
thrombosis, renal damage, and heart failure: high-sensitivity C-reactive protein (hs-CRP), monocyte
chemoattractant protein-1 (MCP-1), galectin-3, N-terminal fragment of brain natriuretic peptide (NT-pro-
BNP), calcidiol (vitamin D metabolite), ﬁbroblast growth factor-23 (FGF-23), parathormone, and phosphate.
Results: Twenty patients (2.8%) exhibited no CRFs. Clinical variables were well balanced in both groups,
with the logical exceptions of no use of antidiabetic drugs, lower triglyceride and glucose, and higher
high-density lipoprotein cholesterol in no-CRF patients.
No-CRF patients showed lower hs-CRP (2.574  3.120 vs. 4.554  9.786 mg/L; p = 0.018), MCP-1
(114.75  36.29 vs. 143.56  65.37 pg/ml; p = 0.003), and FGF-23 (79.28  40.22 vs. 105.17  156.61 RU/ml;
p = 0.024), and higher calcidiol (23.66  9.12 vs. 19.49  8.18 ng/ml; p = 0.025) levels. At follow-up, 10.0% vs.
11.0% patients experienced acute ischemic event, heart failure, or death in the non-CRF and CRF groups,
respectively (p = 0.815, log-rank test). The limited number of non-CRF patients may have inﬂuenced this
ﬁnding. A Cox regression analysis in the whole population showed that high calcidiol, and low MCP-1 and
FGF-23 plasma levels are associated with a better prognosis.
Conclusions: CHD patients without CRFs show a favorable biomarker proﬁle in terms of inﬂammation
and mineral metabolism. Further studies are needed to investigate whether this difference translates
into a better prognosis.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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The importance of cardiovascular risk factors (CRFs) in the
development of coronary heart disease (CHD) is well established,
and it is widely recognized that they must be controlled in order to
halt the progression of the disorder [1]. However, some patients
with CHD do not present with classical CRFs. Although these
patients are managed similarly to patients who have CRFs, they
sometimes show differences as compared to those with CRFs.
Despite this, less attention has been paid to this subgroup.
In recent years there has been a growing interest in the role of
prognostic biomarkers in atherothrombosis. It has been shown
that increased levels of high-sensitivity C-reactive protein (hs-
CRP), monocyte chemoattractant protein-1 (MCP-1), galectin-3,
and N-terminal probrain natriuretic peptide (NT-proBNP) are
related to an adverse prognosis [2–8]. More recently, plasma levels
of the components of mineral metabolism, such as vitamin D,
ﬁbroblast growth factor-23 (FGF-23), parathormone, and phos-
phate have also been related to cardiovascular disorders [9–12].
We have investigated whether CHD patients who do not have
CRFs present a more favorable proﬁle of prognostic biomarkers
related to atherothrombosis. We divided a population of
704 patients with CHD into those with and without CRFs. These
patients were examined according to a panel of biomarkers related
to inﬂammation, thrombosis, renal damage, and heart failure: hs-
CRP, MCP-1, galectin-3, and NT-pro-BNP [2–8]. In addition, we
determined the levels of the components of mineral metabolism in
the patients’ plasma: calcidiol (a metabolite of vitamin D), FGF-23,
parathormone, and phosphate.
Methods
Patients
The research protocol was approved by the ethics committees
of the participating hospitals and all patients signed informed
consent documents. The BACS & BAMI (Biomarkers in Acute
Coronary Syndrome & Biomarkers in Acute Myocardial Infarction)
studies included patients admitted to four hospitals in Madrid who
had either non-ST elevation acute coronary syndrome or ST-
elevation acute myocardial infarction, as described previously
[5]. Exclusion criteria were: age over 85 years, coexistence of other
signiﬁcant cardiac disorders except left ventricular hypertrophy
secondary to hypertension, coexistence of any illness or toxic
habits that could limit patient survival, impossibility to perform
revascularization when indicated, and subjects in whom follow-up
was not possible. In order to limit the variability of the ﬁndings due
to an excessive heterogeneity in the intervals between the acute
event and blood extraction, the investigators agreed to exclude
patients who were not clinically stable at day six of the index
event.
In addition to plasma withdrawal at discharge, a second plasma
sample was extracted between 6 and 12 months later, on an
outpatient basis. This paper reports data from the clinical and
analytic ﬁndings obtained during this second plasma extraction.
Between July 2006 and April 2010, 1898 patients who had
experienced an acute coronary event were discharged from the
participating hospitals. Of these, 838 were included in the study. The
remaining patients were not included due to one of the following
reasons: age over 85 years (17.3%), disorders or toxic habits limiting
survival (29.0%), impossibility to perform cardiac revascularization
(14.5%), coexistence of other signiﬁcant cardiopathy (6.8%),
impossibility to perform follow-up (12.0%), clinical instability
beyond the sixth day at the index event (9.1%), refusal to participate
in the study (2.0%), and impossibility of the investigators to include
them (9.3%). Of the patients included, 7 died before the secondplasma extraction and 709 had available and adequate plasma
samples at the time. This visit took place between January 2007 and
February 2011. The patients were included in a follow-up study,
with the last visits taking place in May 2012. Five patients were lost
to follow-up, leaving a total of 704 patients for analysis.
Study design
The cross-sectional study was carried out during the visit
performed 6–12 months after the acute coronary event. Blood was
withdrawn from the patients for plasma storage and a complete set
of clinical variables was recorded. Twelve-hour fasting venous
blood samples were collected in ethylenediaminetetraacetate tube
(EDTA). Patients were considered to present with hypertension if
they had a history of systolic and/or diastolic pressure equal to or
higher than 140 and 90 mmHg, respectively [13] or if they were
taking blood-pressure-lowering drugs for this disorder. Patients
with current or past tobacco use were considered smokers.
Patients receiving lipid-lowering therapy for this diagnosis and
those with fasting lipid levels (low-density lipoprotein cholesterol
>160 mg/dl and/or triglyceride levels >200 mg/dl) were consid-
ered to be diagnosed with dyslipidemia [14]. Patients were
considered to present a family history of atherosclerosis when a
ﬁrst-degree relative younger than 60 years had history of CHD,
peripheral vascular disease, or cerebrovascular disease [15]. Final-
ly, patients were considered to be diabetics if they were receiving
therapy for the condition or if they had fasting glucose levels
>126 mg/dl [16].
A prospective observational study was also initiated during this
visit. Under the study, patients were seen every year at their
hospital. At the end of follow-up (maximum 4.6 years), the
patients’ medical records were reviewed and patient status was
conﬁrmed by telephone contact made by a cardiologist. The
outcome variable was the combination of acute thrombotic events
(any acute coronary syndrome, stroke, and transient ischemic
attack) plus all-cause mortality and heart failure, deﬁned as
described previously [5].
Biomarker and analytical studies
Venous blood samples were centrifuged at 2500 g for 10 min.
Plasma was stored at 80 8C in the biobank of IIS-Fundacio´n
Jime´nez Dı´az. Plasma determinations of calcidiol, FGF-23, and
intact parathormone were performed at the laboratory of
Nephrology and Mineral Metabolism at the Go´mez-Ulla hospital.
The remaining determinations were carried out at the Vascular
Pathology and Biochemistry Laboratories at Fundacio´n Jime´nez
Dı´az. The investigators who performed the laboratory studies were
unaware of clinical data. Plasma calcidiol levels were quantiﬁed by
chemiluminescent immunoassay (CLIA) using the LIAISON1 XL
analyzer (LIAISON 25OH Vitamin D total Assay, DiaSorin, Saluggia,
Italy), FGF-23 was measured by an enzyme-linked immunosorbent
assay that recognizes epitopes within the carboxyl-terminal
portion of FGF-23 (Human FGF-23, C-Term, Immutopics Inc., San
Clemente, CA, USA), intact parathormone was analyzed by a
second-generation automated chemiluminescent method (Elecsys
2010 platform, Roche Diagnostics, Mannheim, Germany), and
phosphate was determined through an enzymatic method (Integra
400 analyzer, Roche Diagnostics). Plasma concentrations of MCP-1
and galectin-3 were determined in duplicate using commercially
available enzyme-linked immunosorbent assay kits (BMS279/2
Bender MedSystems, Burlingame, CA, USA, and DCP00, R&D
Systems, Minneapolis, MN, USA, respectively) following the
manufacturers’ instructions. Intra- and inter-assay coefﬁcients of
variation were 4.6% and 5.9% for MCP-1 and 6.2% and 8.3% for
galectin-3, respectively. Hs-CRP was assessed by latex-enhanced
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Erlangen, Germany), and NT-pro-BNP was analyzed by immuno-
assay (VITROS, Orthoclinical Diagnostics, Raritan, NJ, USA). Lipids,
glucose, and creatinine determinations were performed by
standard methods (ADVIA 2400 Chemistry System).
Statistical analysis
Quantitative data that followed a normal distribution are
presented as mean  standard deviation and compared using the
Student ‘‘t’’ test. When normal distribution could not be assumed,
median (interquartile range) and Mann–Whitney test were used.
Qualitative variables are displayed as percentages and were
compared by X2 or Fisher’s exact test where appropriate. Log-rank
test was used to compare time to outcome in patients without CRFs
against those who had CRFs. Cox regression analysis was performed
with forward, stepwise selection, to assess the predictive value of theTable 1
Characteristics of patients with and without cardiovascular risk factors.
Characteristics Patients without
CRF (N = 20)
Patien
CRF (
Age (years) 63.45  11.92 61.35  1
Male sex (%) 60.0 75.7 
Family history atherosclerosis (%) 20 24.7 
Body Mass Index 28.13  4.09 28.73  4
Cerebrovascular events (%) 0.0 3.5 
Previous PAD (%) 0.0 3.9 
Previous CABG (%) 5.0 8.5 
Atrial ﬁbrillation 0.0 5.0 
Ejection fraction <40% (%) 15.0 11.7 
ASA (%) 100.0 91.7 
Clopidogrel (%) 75.0 67.5 
Acenocoumarol (%) 0.0 6.0 
Statins (%) 95.0 87.4 
Oral antidiabetic drugs (%) 0.0 18.3 
Insulin (%) 0.0 6.6 
ACEI/ARB (%) 60.0 70.6 
Aldosterone receptor blockers (%) 10.0 5.7 
Beta-blockers (%) 70.0 76.6 
Verapamil (%) 0.0 0.4 
Diltiazem (%) 0.0 3.4 
Dihydropyridines (%) 10.0 16.8 
Data at the previous acute coronary event
Complete revascularization (%) 70.0 65.2 
Number of vessels diseasedc
0 (%) 10.0 9.6 
1 (%) 65.0 52.2 
2 (%) 25.0 25.1 
3 (%) 0.0 10.8 
Analytical data
Total cholesterol (mg/dl) 148.5  23.7 153.3  34
LDL cholesterol (mg/dl) 79.15  21.34 83.27  2
HDL cholesterol (mg/dl) 50.25  11.69 43.63  1
Non-HDL cholesterol (mg/dl) 98.25  23.48 109.25  3
Triglycerides (mg/dl) 95.50  40.25 132.10  8
Glycemia (mg/dl) 93.7  18.30 109.59  3
GFR (CKD-EPI) (ml/min/1.73 m2) 74.77  14.35 75.87  1
Galectin-3 (ng/ml) 7.800 (5.603, 9.373) 7.785 (6
HS C-reactive protein (mg/L) 2.574  3.120 4.554 
Calcidiol (ng/ml) 23.66  9.12 19.49  8
FGF-23 (RU/ml) 79.28  40.22 105.17  1
MCP-1 (pg/ml) 114.75  36.29 143.56  6
NT-ProBNP (pg/ml) 199.5 (105.8, 269.3) 167.0 (87.
Parathormone (pg/ml) 69.45  30.96 65.52  3
Phosphate (mg/dl) 3.28  0.61 3.25  1
ASA, acetylsalicylic acid; CABG, coronary artery by-pass graft; ACEI, angiotensin-conv
kidney disease epidemiology collaboration; CRF, cardiovascular risk factors; FGF-23, 
HDL, high-density lipoprotein; LDL, low-density lipoprotein; MCP-1, monocyte chem
peripheral artery disease. The p bold values are statistically signiﬁcant.
a Group of age- and sex-matched patients with CRF.
b Comparison between non-CRF and age- and sex-matched CRF patients.
c 100% and 97.7% of patients underwent coronary angiography in the non-CRF and Cbiomarkers studied for the development of the outcome, controlling
for all the variables shown in Table 1. Analyses were performed with
SPSS 19.0 (SPSS Inc., New York, NY, USA) and R 3.0.1. (http://
www.r.project.org/).
Results
Of the 704 patients included, only 20 (2.8%) did not present any
classical CRFs. Forty percent of these patients were women
(Table 1). Age was similar in the non-CRF and the CRF groups, and
there were no signiﬁcant differences in the clinical variables
between both groups, with the exception of the intake of
antidiabetic drugs, which was more frequent in the CRF group
(18.3% vs. 0%; p = 0.034). Glucose (93.7 mg/dl vs. 109.6 mg/dl;
p = 0.001) and triglycerides (95.5  40.3 mg/dl vs. 132.1  83.6 mg/
dl; p < 0.001) plasma levels were lower in the non-CRF group than in
patients with CRFs. On the other hand, high-density lipoproteints with
N = 684)
p-Value Patients with
CRF (N = 40)a
p-Valueb
2.28 0.450 64.58  7.75 0.704
0.118 60.0 1.000
0.795 32.5 0.375
.54 0.557 29.07  5.6 0.511
1.000 2.5 1.000
1.000 2.5 1.000
1.000 12.5 0.653
0.617 0.0 –
0.721 12.5 1.000
0.396 90.0 0.291
0.630 70.0 0.769
0.623 2.5 1.000
0.495 87.5 0.653
0.034 10.0 0.291
0.632 2.5 1.000
0.325 72.5 0.384
0.327 0.0 0.107
0.592 77.5 0.542
1.000 0.0 –
1.000 5.0 0.548
0.554 22.5 0.307
0.770 65.0 0.750
0.439 0.230
10.0
40.0
37.5
10.0
.5 0.536 160.7  41.8 0.156
5.77 0.479 89.90  32.17 0.182
0.81 0.007 48.45  12.68 0.597
1.12 0.118 112.22  34.06 0.105
3.57 <0.001 111.48  43.36 0.174
6.99 0.001 113.6  32.1 0.004
9.26 0.799 71.78  17.04 0.462
.023, 9.760) 0.815 8.485 (6.623, 10.058) 0.355
 9.786 0.018 3.913  5.124 0.215
.18 0.025 18.67  7.06 0.023
56.61 0.024 86.678  29.642 0.438
5.37 0.003 158.322  72.665 0.003
6, 419.0) 0.988 203 (96.4, 464.5) 0.583
1.92 0.587 66.226  32.436 0.714
.34 0.874 3.34  0.48 0.424
erting enzyme inhibitors; ARB, angiotensin receptor blockers; CKD-EPI, chronic
ﬁbroblast growth factor-23; GFR, glomerular ﬁltration rate; HS, high-sensitivity;
oattractant protein-1; NT-proBNP, N-terminal probrain natriuretic peptide; PAD,
RF groups, respectively.
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(50.3  11.7 mg/dl vs. 43.6  10.8 mg/dl; p = 0.007).
The biomarker study showed lower hs-CRP (2.574  3.120 mg/L
vs. 4.554  9.786 mg/L; p = 0.018) and MCP-1 (114.75  36.29 pg/ml
vs. 143.56  65.37 pg/ml; p = 0.003) plasma levels in the non-CRF as
compared to the CRF group. The analysis of the components of
mineral metabolism showed lower FGF-23 levels in patients without
CRF as compared to those with CRFs (79.28  40.22 RU/ml vs.
105.17  156.61 RU/ml; p = 0.024). On the other hand, calcidiol
plasma levels were higher in the non-CRF than in the CRF group
(23.66  9.12 ng/ml vs. 19.49  8.18 ng/ml respectively; p = 0.025).
No differences were found in the remaining biomarkers assessed
(Table 1). Using linear regression analysis, we estimated that
glycemia, HDL-cholesterol, and triglyceride plasma levels only
explained 3.0% (R2 = 0.030), 0.1% (R2 = 0.001), 0.3% (R2 = 0.003), and
6% (R2 = 0.062) of the variations in hs-CRP, MCP-1, FGF-23, and
calcidiol levels, respectively.
As the low number of patients without CRFs could have masked
signiﬁcant differences in age and gender, we carried out a new
analysis comparing the non-CRF group to a control group of 40 age-
and sex-matched patients with CRFs. The results of this analysis
were similar to those of the overall assessment (Table 1). There were
lower glucose (93.7  18.3 mg/dl vs. 113.6  32.1 mg/dl; p = 0.004)
and MCP-1 (114.75  36.29 pg/ml vs. 158.32  72.67 pg/ml; p = 0.003)
plasma levels in the non-CRF group. In addition, calcidiol levels were
also higher in the non-CRF than in the CRF group (23.66  9.12 ng/ml
vs. 18.67  7.06 ng/ml; p = 0.023). There was a trend toward a
reduction in FGF-23 and hs-CRP levels in patients without CRF; this
difference failed to reach statistical signiﬁcance, probably due to the
lower sample size of both groups in this conﬁrmation study. Similarly,
differences in the use of oral antidiabetic drugs, and in triglyceride and
HDL plasma levels did not reach statistical signiﬁcance.
After 2.12 (1.37–2.98) years of follow-up, 2 patients (10%) in the
non-CRF group and 75 patients (10.96%) in the CRF group reached
the prespeciﬁed outcome. Of the 2 patients in the non-CRF group,
1 suffered a stroke and the other developed a non-ST segment
elevation myocardial infarction. In the CRF group, there were
38 non-ST segment elevation acute coronary syndromes, 4 cases of
ST-segment elevation myocardial infarction, 7 strokes, 10 transito-
ry ischemic attacks, 16 hospital admissions due to heart failure,
and 22 deaths. Twelve patients developed two events and ﬁve
patients experienced three events. There were no signiﬁcant
differences between the two groups (p = 0.816, log-rank test).
All variables shown in Table 1 were entered into a multivariate
Cox model to investigate the predictive value of the biomarkers
studied in the whole population. In this analysis, low calcidiol and
high FGF-23 and MCP-1 plasma levels were independent
predictors of outcome, along with age, insulin, and angiotensin-
converting enzyme inhibitor or angiotensin receptor blocker
treatment (Table 2).Table 2
Multivariable Cox model for the incidence of the outcome.
Hazard ratio 95% CI p-Value
Lower Upper
Age 1.054 1.030 1.078 <0.001
Insulin 2.517 1.103 5.746 0.028
ACEI/ARB 0.567 0.336 0.959 0.034
Calcidiol 0.964 0.930 0.999 0.042
MCP-1 1.311a 1.072a 1.604a 0.008
FGF-23 1.112b 1.015b 1.218b 0.023
CI, conﬁdence interval; ACEI, angiotensin-converting enzyme inhibitors; ARB,
angiotensin receptor blockers; MCP-1, monocyte chemoattractant protein-1;
FGF-23, ﬁbroblast growth factor-23.
a Increase in hazard ratio per 100 pg/ml.
b Increase in hazard ratio per 100 RU/ml.Discussion
Most patients with established CHD have some classical CRF.
Nonetheless, a small proportion of them are free of CRFs. However,
little attention has been paid to these patients.
Only 20 out of the 704 patients (2.8%) included in our study had
no CRFs. This value is lower than those reported previously
[17]. The published data vary depending on the population
analyzed, cut-off values used in the deﬁnition of CRFs, and age.
The absence of traditional CRFs in patients with atherosclerosis is
not surprising, since other CRFs may contribute to this disorder
[18]. In addition, other factors such as inﬂammation may promote
atherosclerosis [19].
Age is considered an independent CRF [1], and the proportion of
patients without classical CRFs increases with age [17], as we
observed in our study. Of interest, the prognostic power of classical
CRFs diminishes with increasing age [20] suggesting that their role in
the development of CHD may be more important in young subjects.
Male gender is also correlated with higher cardiovascular risk [21],
and in our population there was a higher proportion of men than
women. However, we did not ﬁnd signiﬁcant differences in gender
distribution between patients with and without CRFs, although this
could be due to the small number of patients without CRFs.
Both groups showed a similar distribution of clinical variables;
the only exception to this was that the CRF group contained more
patients under oral antidiabetic therapy. This difference is logical
as, by deﬁnition, diabetic patients could only belong to the CRF
group. Although similar data could be expected to be present with
regard to the use of lipid- and blood pressure-lowering drugs, this
was not the case. The percentage of patients receiving treatment
with statins was similar in both groups, because aggressive lipid
lowering is indicated in all patients after an acute coronary event
[22]. With regard to antihypertensive patients, modulators of the
renin–angiotensin system are indicated in subjects with clinically
evident atherosclerosis, and even more when left ventricular
dysfunction is present [22]. Similarly, beta-blockers are beneﬁcial
in patients with a history of myocardial infarction [22]. Other blood
pressure-lowering drugs such as diuretics may be advised in more
patients in addition to those with hypertension, such as patients
who have experienced heart failure. Finally, patients without CRFs
had lower glycemia, higher HDL-cholesterol, and lower triglycer-
ide plasma levels than those with CRFs, according to the criteria
used to allocate them into one of the two groups.
Inﬂammation is an important process both in atherogenesis and
plaque complications [19]. Furthermore, some inﬂammatory
markers predict cardiovascular events even in patients without
CRFs. In this regard, the ABC study showed that levels of
interleukin-6 predicted CHD in elderly patients even in the
absence of CRFs [20].
Hs-CRP plasma levels have been associated with an increased
incidence of cardiovascular events [2,3]. In our study, patients
without CRFs had lower hs-CRP levels than those with classical
CRFs. Accordingly, MCP-1 plasma levels were also lower in patients
without CRFs. MCP-1 is the most important chemokine involved in
the atherothrombotic process, and it is vital to the recruitment of
macrophages into the vessel wall [23]. It is expressed more
strongly in atherosclerotic lesions than in healthy vessels
[24]. Drugs with antiatherosclerotic effects, such as statins,
decrease MCP-1 expression in the vascular wall [25]. Furthermore,
MCP-1 also has procoagulant properties [26]. According to this
evidence, increased MCP-1 plasma levels have been found to
predict the development of adverse cardiovascular events in
patients with acute coronary syndromes and stable CHD [4,5].
Although traditionally related to renal disease, abnormalities in
mineral metabolism have been associated with cardiovascular
disease more recently. When there is a decrease in renal
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maintain phosphate homeostasis, there is an increase in FGF-23
and parathormone plasma levels. Enhanced plasma levels of
phosphate, FGF-23, and parathormone have been related to an
increase in cardiovascular events through different mechanisms,
including endothelial dysfunction, arterial stiffness, and left
ventricular hypertrophy [9,10,12,27]. In addition, FGF-23 reduces
vitamin D plasma levels [10]. This enhances cardiovascular risk
even more, as low vitamin D levels are associated with endothelial
dysfunction, inﬂammation, activation of the renin–angiotensin
system, vascular smooth muscle cell proliferation, and vascular
calciﬁcation, resulting in increased risk of hypertension, CHD, and
stroke [11,28–31]. In our population, subjects without CRFs not
only exhibited lower FGF-23 plasma levels, but also revealed
increased calcidiol levels. This is especially important, since the
combination of vitamin D deﬁcit along with increased FGF-23
plasma levels seems to confer a higher cardiovascular risk [32].
It is possible that a causal relationship between the absence of
classical CRFs and the more favorable biomarker proﬁle described
in this population exists. In this regard, diabetes has been
associated with enhanced MCP-1 expression [33] and HDL has
been shown to decrease the expression of this cytokine [34]. Fur-
thermore, vitamin D decreases MCP-1 secretion in U937 mono-
cytes in the presence of high glucose concentrations [35]. Finally,
FGF-23 decreases synthesis and enhances catabolism of vitamin D
[10]. Nevertheless, in the present paper, we have not addressed
this issue, and more investigations are needed to elucidate the
links between the absence of CRFs and the biomarker proﬁle
reported in this paper.
The diminution in hs-CRP, MCP-1, and FGF-23 plasma levels,
along with the increase in calcidiol levels appears to correlate with
a more favorable prognosis in patients without CRFs. Although this
improved prognosis was not conﬁrmed in our population, this
could be due to the low number of patients who had no CRFs. Given
the low percentage of CHD patients without CRFs, conﬁrmation of a
better prognosis would require a large sample size.
However, we show that in our whole population low calcidiol
and high MCP-1 and FGF-23 plasma levels were independent
predictors of the outcome, suggesting that the biomarker proﬁle on
non-CRF patients may be related with a more favorable prognosis.
This work has some limitations. (1) Excluding patients with
clinical instability in the ﬁrst days after the index event could have
introduced a certain bias, because these patients would probably
have had a worse prognosis, and could have also a different
distribution of CRFs. (2) The low number of patients without CRF in
our population could have limited the statistical power in the
prognosis assessment. This suggests that large sample sizes of
patients with CHD must be examined in order to reach more sound
conclusions with regard to potential differences in the prognosis of
both groups. (3) We have not assessed these biomarkers in the
acute phase of the study as, at the time of the acute event, the
population was not homogeneous as there were patients with both
ST-elevation and non-ST elevation acute coronary syndromes.
Then, plasma analysis at this time would imply mixing patients
with two different clinical pictures. (4) Finally, it must be
emphasized that we have published previously Cox regression
analyses in this population to explore separately the predictive
power of MCP-1 [5] and that of calcidiol and FGF-23 plasma levels
[32]. In the present paper, we have reanalyzed these biomarkers
together to support the hypothesis that the biomarker proﬁle of
non-CRF patients may be associated with a more favorable
prognosis.
In conclusion, patients with CHD who do not present with CRFs
display lower plasma levels of inﬂammatory biomarkers and a
better proﬁle in the mineral metabolism than those with CRFs.
These ﬁndings could be related to a better prognosis, although wecould not conﬁrm this difference given the low number of subjects
without CRFs found in our population. Further studies in large
numbers of CHD patients are needed in order to conﬁrm this
hypothesis.
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